The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Share News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: Rosslyn promotes new CEO; Celtic CEO ready to start

Tue, 06th Apr 2021 14:54

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Tuesday and not separately reported by Alliance News:

----------

GlaxoSmithKline PLC - Brentford, Middlesex-based pharmaceutical firm - Hires Anne Beal as non-executive director, starting May 6. Beal will replace Lynn Elsenhans as chair of the Corporate Responsibility Committee, and Elsenhans will stay on the board for an additional year to allow for a handover. Beal is founder and chief executive officer of AbsoluteJOI Skincare. She spent six years at Harvard Medical School and Massachusetts General Hospital, instructing in paediatrics.

----------

Assura PLC - Warrington, England-based primary care property investor - Jenefer Greenwood will retire as non-executive director at Assura's July 6 annual general meeting. Hires Emma Cariaga, Noel Gordon and Sam Barrell as new non-executive directors, starting on May 1. Cariaga is joint head of Canada Water Development on the executive committee of British Land Co PLC. Gordon was global managing director at consultants Accenture. For the UK National Health Service, he was chair of NHS Digital and a non-executive director of NHS England. Barrell is chief operating officer of the Crick Institute, which supports biomedical research.

----------

Rosslyn Data Technologies PLC - London-based cloud enterprise data analytics platform - Chief Executive Officer Roger Bullen steps down from board, effective immediately, but will remain as an adviser for six months. Bullen served for five years as CEO and chief financial officer. Chief Customer Officer Paul Watts is promoted to CEO. Watts joined Rosslyn back in August and before that was CEO of Blue Prism KK Japan, a robotic process automation company. Both Chair James Appleby and CFO Ash Mehta will take on additional responsibilities. Rosslyn also says it expects its results for the financial year ending April 30 to be in line with market expectations. It will issue a trading update in late May.

----------

Celtic PLC - Glasgow football club - Confirms that Dominic McKay will join Celtic on April 19 before replacing retiring Peter Lawwell as chief executive on July 1. Scottish Rugby confirmed that McKay will leave as chief operating officer on April 16, following a successful handover. McKay, who also was chair of the Guinness Pro14 annual rugby union competition, will join the Celtic board.

----------

Amryt Pharma PLC - London-based biopharmaceutical firm focused on rare and orphan diseases - Hires Sheila Frame as president for the Americas. Frame has held senior positions at Novartis AG, Bristol-Myers Squibb Co and AstraZeneca PLC.

----------

MyHealthChecked PLC - Cardiff-based consumer home-testing healthcare - Peter Dines steps down as non-executive director on Tuesday. Dines is chief operating officer of Mercia Asset Management PLC, whose funds have a 28% stake in MyHealthChecked. He is standing down to focus on other portfolio companies.

----------

Northamber PLC - Chessington, Surrey-based audio-visual and information technology distributor - Promotes Finance Director Tony Lee to board and hires Riccardo Reggio as a non-executive director, both from last Thursday. Lee re-joined Northamber in August of last year, having previously been finance director from 2003 to 2005. Reggio is a corporate strategy and acquisitions adviser who worked at Monitor Group for 15 years.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
28 Feb 2019 14:06

Redx Pharma Issues 750,000 Shares In Order To Reduce Headquarter Lease (ALLISS)

LONDON (Alliance News) - Biotechnology firm Redx Pharma PLC on Thursday said it has changed the lease agreement at its Alderley Park headquarters in Cheshire, England, reducing the amount of will

Read more
28 Feb 2019 12:12

Amryt Pharma Now Permitted To Enrol Children Under Four In Ease Trial

LONDON (Alliance News) - Amryt Pharma PLC on Thursday said it now has permission to enrol infants and children under four years old in its ongoing phase three Ease trial of AP101 in the Ease will

Read more
7 Jan 2019 09:41

Amryt Pharma Reports Positive Results For Gene Therapy In Skin Disease

LONDON (Alliance News) - Amryt Pharma PLC on Monday reported positive results from two pre-clinical studies of its novel non-viral gene therapy for recessive dystrophic epidermolysis company said

Read more
4 Jan 2019 14:41

Amryt Pharma given go-ahead to continue Phase III EASE trial

(Sharecast News) - Revenue-generating orphan drug company Amryt Pharma announced the results of an unblinded interim efficacy analysis on its pivotal Phase III EASE trial for AP101 as a potential treatment for Epidermolysis Bullosa (EB) on Friday.

Read more
4 Jan 2019 13:32

Committee Recommends Adding More Patients To Amryt Pharma's Ease Trial

LONDON (Alliance News) - Amryt Pharma PLC on Friday said an independent data monitoring committee has recommended adding more patients to its phase three Ease trial of epidermolysis bullosa drug a

Read more
19 Dec 2018 11:22

Amryt Pharma flags slight delay to EASE trial data

(Sharecast News) - Orphan drug company Amryt Pharma updated the market on the global AP101 EASE Phase III clinical trial being conducted in patients with Epidermolysis Bullosa (EB) on Wednesday, reporting that the independent data monitoring committee was scheduled to meet on 21 December to review the EASE unblinded interim efficacy analysis results.

Read more
10 Dec 2018 16:39

Amryt Pharma scores €8.4m grant from Irish government

(Sharecast News) - Amryt Pharma announced on Monday that it has secured am €8.4m grant from the Irish Government for three years of development of its AP103 gene therapy platform.

Read more
10 Dec 2018 12:12

Amryt Pharma Secures Irish Government Grant To Develop AP103 Platform

LONDON (Alliance News) - Amryt Pharma PLC on Monday said it has secured grant funding of EUR8.4 million over three years to develop its AP103 gene therapy platform.Amryt shares were trading

Read more
17 Oct 2018 11:31

Amryt Pharma reaches agreement with French authorities over Lojuxta

(Sharecast News) - Orphan drug company Amryt Pharma has reached agreement with France's Comité économique des produits de santé (CEPS) to reimburse 'Lojuxta' (lomitapide) for the treatment of adult patients with homozygous familial hypercholesterolaemia (HoFH) in France.

Read more
26 Sep 2018 12:47

Amryt Narrows Half Year Loss On Lojuxta Sales And Lower Expenses

LONDON (Alliance News) - Oprhan drug company Amryt Pharma PLC said Wednesday its loss narrowed in the first half of 2018 due to increased sales of its rare disease drug Lojuxta and reduced the six

Read more
2 Aug 2018 12:15

Amryt Pharma Gets Rare Pediatric Disease Designation For AP101

LONDON (Alliance News) - Amryt Pharma PLC said Thursday that the US Food & Drug Administration has granted a rare pediatric disease designation for AP101, used for the treatment of Bullosa is

Read more
19 Jul 2018 12:47

Amryt Pharma Confident In 2018 With Strong First-Half Revenue Growth

LONDON (Alliance News) - Amryt Pharma PLC said on Thursday it expects its performance for 2018 to be in line with current market expectations, following strong trading in the first half.The

Read more
9 Jul 2018 10:46

Amryt Pharma Gets NHS Approval For Cholesterol Drug Lojuxta

LONDON (Alliance News) - Amryt Pharma PLC on Monday said its cholesterol reducing drug, Lojuxta, has been approved by the NHS in England.The pharmaceutical company, which focuses on rare in

Read more
29 May 2018 10:54

Amryt Pharma Gets Four Distribution Deals For Lojuxta In Middle East

LONDON (Alliance News) - Amryt Pharma PLC on Tuesday said it signed four distribution deals for its cholesterol disorder drug Lojuxta across the Middle East.The biopharmaceutical company it

Read more
10 May 2018 13:25

Amryt Pharma Extends Lojuxta Licence Deal Into New Territories

LONDON (Alliance News) - Amryt Pharma PLC on Thursday said it has expanded its Lojuxta licence agreement with Aegerion Pharmaceuticals Inc into Russia, the Commonwealth of Independent States, and

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.